<div id="readability-page-1"><div><p>Alset Inc.'s (NASDAQ:AEI) value has fallen 16% in the last week, but insiders who sold US$2.7m worth of stock over the last year have had less success.  Insiders would probably have been better off holding on to their shares given that the average selling price of US$2.67 is still lower than the current share price.</p><p> While insider transactions are not the most important thing when it comes to long-term investing,  we would consider it foolish to ignore insider transactions altogether. </p> <p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p><h2> Alset Insider Transactions Over The Last Year </h2> <p> Over the last year, we can see that the biggest insider sale was by the Founder, Heng Fai Chan, for US$1.3m worth of shares, at about US$2.67 per share.   While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price.  The good news is that this large sale was at well above current price of US$1.60.  So it may not shed much light on insider confidence at current levels.    Heng Fai Chan was the only individual insider to sell shares in the last twelve months.    Notably Heng Fai Chan was also the biggest buyer, having purchased US$43k worth of shares.   </p> <p> Heng Fai Chan sold a total of 1.00m shares over the year at an average price of US$2.67.   You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below.  If you want to know exactly who sold, for how much, and when, simply click on the graph below! </p><p><span> View our latest analysis for Alset </span></p><p> If you like to buy stocks that insiders are buying, rather than selling, then you might just love this <strong>free</strong> list of companies. (Hint: Most of them are flying under the radar). </p> <h2> Insider Ownership Of Alset </h2><p> For a common shareholder, it is worth checking how many shares are held by company insiders.  I reckon it's a good sign if insiders own a significant number of shares in the company.   It's great to see that Alset insiders own 90% of the company, worth about US$58m.  I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.  </p><h2> What Might The Insider Transactions At Alset Tell Us? </h2><p> There haven't been any insider transactions in the last three months -- that doesn't mean much.      While we feel good about high insider ownership of Alset, we can't say the same about the selling of shares.       So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company.    Every company has risks, and we've spotted <strong>4 warning signs for Alset</strong> (of which 1 is potentially serious!) you should know about.   </p><p> If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this <strong>free</strong> list of interesting companies, that have HIGH return on equity and low debt. </p><p><em>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.</em></p></div></div>

SBIO

LABU

<p>Alset Inc. (NASDAQ:AEI) has seen a 16% decline in value over the past week. Insiders sold $2.7 million worth of stock, with the largest sale by Founder Heng Fai Chan at $1.3 million, averaging $2.67 per share, which is higher than the current price of $1.60. Despite high insider ownership of 90%, the selling raises concerns about insider confidence. No insider transactions occurred in the last three months, highlighting potential risks for the company.</p>

Simplywall

Alset

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Insider Sellers Might Regret Selling Alset Shares at a Lower Price Than Current Market Value